KURA — Kura Oncology, Inc.

Kura Oncology Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Collaboration Revenue: $20.8 million from the partnership with Kyowa Kirin, up from $0 in Q3 2024.
• R&D Expenses: Increased to $67.9 million from $41.7 million year-over-year.
• G&A Expenses: Rose to $32.8 million from $18.2 million year-over-year.
• Net Loss: Reported at $74.1 million, compared to a net loss of $54.4 million in Q3 2024.
• Cash Position: As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $549.7 million, with a pro forma cash position of $609.7 million after accounting for recent milestone payments.

2. Strategic Updates and Business Highlights

• Ziftomenib Development: The FDA review for ziftomenib, a menin inhibitor for acute myeloid leukemia (AML), is on track with a PDUFA date of November 30, 2025. Positive clinical data from the KOMET-001 study supports its differentiated profile.
• Commercial Readiness: Kura's commercial team is fully prepared for the launch of ziftomenib, with successful disease awareness campaigns and a robust distribution network in place.
• Farnesyl Transferase Inhibitor Program: New clinical data presented indicate promising safety and efficacy profiles for darlafarnib and tipifarnib in combination therapies, positioning this portfolio as a significant growth pillar.

3. Forward Guidance and Outlook

• Upcoming Milestones: Anticipated presentations at the ASH Annual Meeting in December 2025, including updated data on ziftomenib in various settings. Plans to initiate additional clinical trials in 2026.
• Financial Outlook: Kura expects sufficient financial resources to support operations through 2027, bolstered by anticipated milestone payments totaling approximately $315 million.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The net loss widened compared to the previous year, raising concerns about the sustainability of current spending levels.
• Competitive Pressures: Kura faces challenges from competitors with established products in the market, particularly regarding prescriber inertia and the need to differentiate ziftomenib effectively.
• Regulatory Environment: While current interactions with the FDA are constructive, the ongoing disruptions within the agency raise concerns about potential delays or changes in the approval process.

5. Notable Q&A Insights

• Market Penetration Strategy: Kura aims to target specialty hematologists and large academic institutions, with a focus on demonstrating the favorable benefit-risk profile of ziftomenib to overcome the first-mover advantage of competitors.
• ASH Presentation Expectations: The upcoming presentations will provide more comprehensive data, including longer follow-up and subgroup analyses, which are expected to highlight ziftomenib's efficacy and safety.
• FDA Engagement: Management expressed confidence in their ongoing discussions with the FDA, indicating no anticipated changes to the timeline for ziftomenib's approval despite broader agency disruptions.

Overall, Kura Oncology is positioned for a significant launch of ziftomenib, backed by a strong financial position and promising clinical data, while navigating competitive and regulatory challenges in the oncology landscape.